Monsanto Just Rejected Bayer’s Latest Buyout Offer

<a href="http://www.shutterstock.com/gallery-653380p1.html?cr=00&pl=edit-00">B Brown</a>/Shutterstock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Update (7/19/2016): Monsanto formally rejected German chemical giant Bayer’s latest, sweetened buyout bid Tuesday, issuing a statement calling the offer “financially inadequate and insufficient.” But merger talks will apparently grind on. “Monsanto remains open to continued and constructive conversations with Bayer and other parties to assess whether a transaction that the Board believes is in the best interest of Monsanto shareowners can be realized,” the statement says. Last week, Bloomberg reported that Monsanto is also in talks with Bayer’s rival BASF about a possible tie-up.

“We work to help farmers produce food in a sustainable way,” states Monsanto’s website. “Monsanto uses plant breeding and biotechnology to create seeds that grow into stronger, more resilient crops that require fewer resources.” The company even claims its widely used Roundup Ready crops—genetically modified to withstand the herbicide glyphosate—have allowed farmers to “decrease the overall use of herbicides.”

But does Monsanto actually want to wean farmers off pesticides? Its business maneuvers suggest otherwise. Last year, the company—by far the globe’s market leader in seed sales but just the fifth-largest pesticide purveyor—made an extended bid to buy rival Syngenta, the world’s biggest pesticide producer. By committing $45 billion to buy what amounted to a vast pesticide portfolio, Monsanto seemed to be distancing itself from old claims that biotech seeds would make industrial agriculture less chemical-dependent. The Syngenta deal ultimately collapsed, but Monsanto’s thirst to bolster its pesticide holdings appears to remain strong, as its current merger talks with German chemical giant Bayer show.

Monsanto seemed to be distancing itself from old claims that biotech seeds would make industrial agriculture less chemical-dependent.

Now, it’s true that it’s Bayer trying to buy Monsanto, not the other way around. On May 10 Bayer proposed taking over Monsanto in a deal valued at $62 billion. Monsanto’s leadership formally rejected the bid as “incomplete and financially inadequate,” but declared itself “open to continued and constructive conversations.” In trading Tuesday afternoon, Monsanto’s share price was up more than 2 percent—a sign that investors think Bayer will come back with an offer high enough to tempt Monsanto execs.

But I’ve found something interesting in Bayer management’s formal letter to Monsanto CEO Hugh Grant, which is dated May 10 and was released by Bayer last week. Here’s how the letter opens:

Dear Hugh,

Thank you for taking the initiative to arrange the recent meeting between us on April 18, 2016. I appreciated the opportunity to hear your views on the value of a globally integrated agriculture platform and your vision that a combination of Seeds & Traits, Crop Protection, Biologics, and Digital Farming would be a winning formula.

So, according to this letter—signed by Bayer Chairman Werner Baumann and Liam Condon, president of the company’s crop science division—it appears that it could have been Monsanto that initiated talks about a possible tie-up with Bayer. To understand why that’s interesting requires a little background.

After Syngenta definitively rejected the offer last November, Monsanto was widely rumored to be approaching Bayer and rival German chemical giant BASF, to see if either of those companies might be willing to sell off their considerable pesticide interests.

But a few months later, on April 6—four days before the meeting Grant “initiated” with Bayer, according to the letter—Grant himself publicly announced the company has stopped shopping for a big pesticide buy. On a call with Wall Street analysts, Grant claimed that Monsanto “no longer sees large-scale M&A [mergers and acquisitions] as a likely opportunity.” He added: “Let me be clear. Our strategy is not and was not dependent on large-scale M&A.”

My guess is that Monsanto was trying to talk Bayer into selling off its pesticide unit, and Bayer turned around and said, “No thanks; how about we buy you instead?”

As it happens, I visited Monsanto’s global R&D center in suburban St. Louis on April 8, touring the facility and speaking at length with Robb Fraley, Monsanto’s chief technology officer. I asked Fraley that day whether Monsanto’s quest for a big pesticide acquisition was ongoing. He referred me to Grant’s statement from two days before about how the search was over.

Now we know that while publicly abandoning its push to get bigger, Grant was privately wooing Bayer. We don’t know exactly what Grant had in mind. According to a statement from Monsanto, “The principal purpose of the meeting on April 18 was simply to meet Bayer’s new incoming CEO. As is our policy, we wouldn’t have further details to share of the private meeting beyond that though.”

But we do know that Bayer is a huge player in pesticides—it has an 18 percent share in the global pesticide market, second only to Syngenta.

My guess is that Monsanto was trying to talk Bayer into selling off its pesticide unit, and Bayer turned around and said, “No thanks; how about we buy you instead?”

Again, Monsanto declined to comment on the purpose of the April 18 meeting. A company spokeswoman pointed out that Monsanto’s goal for a while, even before the current wave of industry consolidation, has been to act as an “integrated solutions approach for growers”—that is, it wants to be able to offer farmers a complete, one-stop package: seeds, GM traits, pesticides, and advice on how to deploy it all, through its “digital farming” arm.

If Bayer’s bid ends up being successful, it will be the latest marriage in a mating frenzy among the handful of companies that dominate the global seed and pesticide markets. Syngenta fled Monsanto’s embrace and jumped into the arms of ChemChina, the Chinese behemoth, instead. And late last year, US chemical giants Dow and DuPont agreed to merge and announced a plan to spin out their combined agribusiness holdings. If the deal passes regulatory muster, DowDuPont’s agribusiness arm will be the globe’s biggest seed/pesticide company.

Before the consolidation craze started, the same six companies controlled about more than 70 percent in the global markets for seeds and pesticides, according to the watchdog ETC Group. If Bayer gets its way, there will only be four. And that will give the remaining firms unprecedented power to decide what farmers grow and how they grow it.

This post has been updated.

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate